Charles Schwab Investment Management Inc. Grows Position in The Chemours Company (NYSE:CC)

Charles Schwab Investment Management Inc. raised its holdings in The Chemours Company (NYSE:CC - Free Report) by 2.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,229,052 shares of the specialty chemicals company's stock after buying an additional 32,590 shares during the period. Charles Schwab Investment Management Inc. owned about 0.82% of Chemours worth $24,974,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in CC. Matrix Trust Co acquired a new stake in shares of Chemours in the 3rd quarter valued at about $25,000. Blue Trust Inc. boosted its holdings in shares of Chemours by 166.9% in the third quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company's stock valued at $26,000 after acquiring an additional 731 shares during the period. Signaturefd LLC grew its position in shares of Chemours by 163.7% during the third quarter. Signaturefd LLC now owns 1,959 shares of the specialty chemicals company's stock worth $40,000 after acquiring an additional 1,216 shares during the last quarter. Itau Unibanco Holding S.A. acquired a new stake in Chemours during the 2nd quarter worth $58,000. Finally, Prospera Private Wealth LLC purchased a new position in Chemours during the 3rd quarter worth $75,000. 76.26% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Chemours news, SVP Alvenia Scarborough sold 7,500 shares of Chemours stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $20.64, for a total value of $154,800.00. Following the completion of the sale, the senior vice president now directly owns 16,645 shares of the company's stock, valued at approximately $343,552.80. The trade was a 31.06 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.47% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

CC has been the topic of a number of research reports. The Goldman Sachs Group lowered their price target on Chemours from $29.00 to $23.00 and set a "neutral" rating on the stock in a report on Tuesday, September 3rd. Royal Bank of Canada cut their price target on Chemours from $28.00 to $25.00 and set an "outperform" rating for the company in a research note on Wednesday, November 6th. Morgan Stanley lowered their price objective on shares of Chemours from $30.00 to $25.00 and set an "equal weight" rating on the stock in a research report on Tuesday, November 5th. BMO Capital Markets upped their price objective on shares of Chemours from $30.00 to $32.00 and gave the stock an "outperform" rating in a research report on Monday, October 7th. Finally, Barclays lifted their target price on shares of Chemours from $21.00 to $23.00 and gave the company an "equal weight" rating in a report on Tuesday, November 5th. Five research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Chemours currently has an average rating of "Hold" and a consensus price target of $24.88.

Chemours Price Performance

CC stock traded down $0.10 during trading on Friday, reaching $21.00. 1,208,958 shares of the company were exchanged, compared to its average volume of 1,566,448. The company has a debt-to-equity ratio of 6.05, a quick ratio of 0.92 and a current ratio of 1.73. The stock's 50 day moving average price is $19.87 and its 200 day moving average price is $21.14. The Chemours Company has a 52-week low of $15.10 and a 52-week high of $32.70. The company has a market cap of $3.14 billion, a P/E ratio of 42.20 and a beta of 1.80.

Chemours (NYSE:CC - Get Free Report) last posted its earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.08. The company had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.44 billion. Chemours had a return on equity of 29.48% and a net margin of 1.34%. Chemours's revenue was up .9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.64 earnings per share. As a group, analysts predict that The Chemours Company will post 1.35 earnings per share for the current fiscal year.

Chemours Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 16th. Shareholders of record on Friday, November 15th will be issued a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a yield of 4.76%. The ex-dividend date of this dividend is Friday, November 15th. Chemours's dividend payout ratio (DPR) is presently 200.00%.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.